Arid2 Antibodies

AT-rich interactive domain-containing protein 2 (Arid2)

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of this SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF).

May be involved in targeting the complex to various genes. May be involved in regulating transcriptional activation of cardiac genes.

Gene Information

Mouse
Gene Name:	Arid2
Uniprot:	E9Q7E2
Entrez:	77044

Family

Belongs to:
RFX family

Alternative Names

ARID domain-containing protein 2; AT rich interactive domain 2 (ARID, RFX-like); BAF200KIAA1557AT-rich interactive domain-containing protein 2; BRG1-associated factor 200; DKFZp686G052; DKFZp779P0222; FLJ30619; p200; Zinc finger protein with activation potential; zipzap; zipzap/p200

Molecular Weight

Mass (kDA):
195.988 kDA

Genomic Context

Mouse
Location:	15|15 F1
Sequence:	15;

Tissue Specificity

Highly expressed in testis, expressed in heart, liver and kidney.

Diseases

• Malignant Neoplasms
• Liver Carcinoma
• Carcinoma
• Neoplasms
• Liver Neoplasms
• Hepatitis
• Hepatitis B
• Hepatitis C
• Carcinogenesis
• Infective Disorder
• Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

• Melanoma
• Hepatitis C, Chronic
• Synovial Sarcoma
• Malignant Neoplasm Of Liver
• Sarcoma
• Retinoblastoma
• Carcinoma, Pancreatic Ductal

Pathways

• Osteoblast Differentiation
• Axon Guidance
• Dna Repair
• Chromatin Modification
• Pathogenesis
• Chromatin Remodeling

• Lymphocyte Activation

PTMs

• Acetylation
• Isopeptide bond

• Phosphoprotein
• Ubl conjugation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/Arid2

Best Uses Of The ARID2 Marker

The ARID2 gene is a unique protein that is highly expressed in the body. High-affinity primary antibodies to the ARID2 gene are essential for many types of experiments. These antibodies are made using gene infographics. The ARID2 gene is a member of the ras family. It has been shown to be expressed in a variety of tissues, including the liver.

Gene infographics

The ARID2 gene is a tumor suppressor. It physically interacts with E2F1 and reduces binding to the CCND1 promoters, thus suppressing tumor cell growth, cell cycle progression, and proliferation. Thus, it may be an important tumor suppressor in HCC. To further explore this gene, click the Gene Infographics tab and enter the gene you're interested in.

High-affinity primary antibodies

We have previously described high-affinity primary antibodies using the ARID2-MiR-155 marker. Using the miR-155 target gene, we were able to bind this RNA to target DNA or proteins. We then used these antibodies to detect miR-155 in a range of tumors. We first used the miR-155 marker to validate that miR-155 acts as an inhibitor on ARID2, which is a common target for tumor cells.

In mice, the IgD gene is crucial for the proper function of B cells. It controls the maturation and duration of primary autoreactive IgM responses, which in turn protect the autoantigen. Mice lacking IgD produce an increased number of autoreactive IgG antibodies, which cause autoimmune disease. These antibodies recognize DNA and nuclear structures. For example, mice that lack secreted IgM develop high levels of anti-dsDNA-IgG antibodies at a young age.

The KD value, or equilibrium dissociation constant (KD), represents the strength of binding between an antibody and a ligand. KD values are inversely related to affinity. The lower the value, the higher the affinity. Abcam scientists carried out all the experiments and analyzed the results using the ARID2-MiR markers. This method also allows researchers to determine the KD value of an antibody.

The ARID2 marker is a subunit of the PBAF chromatin-remodeling complex. It facilitates ligand-dependent transcriptional activation by nuclear receptors. However, these antibodies cannot be used for diagnostic procedures or resale without authorization. As with all antibodies, they are intended for research purposes only. They are not intended for diagnostic procedures or for the treatment of disease. However, they do offer direct technical assistance and expert recommendations for common problems.

In addition to the ARID2 marker, another method is the use of the 'Stain-Mound' technique. This technique requires the use of an insulin-bio-specific IgM. The latter method allows the antibody to bind to an antigen, and the results are reported in relative units. The ARID2 marker is also useful for high-affinity primary antibodies to detect glioma cells.

In the study, we used the hen-egg lysozyme (HEL) as a model antigen. Using a polyvalent antigen, we showed that the IgD-class BCR induced a calcium flux, and monovalent HEL blocked the activation of IgD-class B cells with complex HEL. This suggests that the flexible hinge region plays a role in the maturation process of B-lymphocytes.

We have used this marker to create high-affinity primary antibodies to detect biotin-conjugated peptides. The results were consistent with serum immunoglobulin data. The ARID2 marker allows us to target cells that secrete IgM-IgG antibodies to specific antigens. In a previous study, we used polyclonal rat IgG-UNLB as the marker to detect biotin-conjugated peptides.